Difference between revisions of "David Haslam (GP and obesity specialist)"

From Powerbase
Jump to: navigation, search
(Affiliations: new chair of iGlobalfitness medical board)
m (adding categories)
 
(12 intermediate revisions by 2 users not shown)
Line 1: Line 1:
Dr David W Haslam is a general practitioner with a special interest in obesity and and cardiometabolic disease. He is a physician in Obesity Medicine at the [[Centre for Obesity Research]] at Luton & Dunstable Hospital, and Chair of the UK's [[National Obesity Forum]] (NOF). <ref> National Obesity Forum, [http://www.nationalobesityforum.org.uk/about-us/the-nof-trustees-mainmenu-159/122-dr-david-haslam.html Dr David Haslam], last accessed 6 October 2010. </ref>
+
{{Template:Foodspin badge}}
 +
Dr '''David W Haslam''' is a general practitioner with a special interest in obesity and and cardiometabolic disease. He is a physician in Obesity Medicine at the [[Centre for Obesity Research]] at Luton & Dunstable Hospital, and Chair of the UK's [[National Obesity Forum]] (NOF). <ref> National Obesity Forum, [http://www.nationalobesityforum.org.uk/about-us/the-nof-trustees-mainmenu-159/122-dr-david-haslam.html Dr David Haslam], last accessed 6 October 2010. </ref>
  
 +
== Activities ==
 +
 +
=== Debate over obesity drugs efficacy ===
 +
 +
On 19 Nov 2007 a new study reported in the British Medical Journal (BMJ) showed that anti-obesity treatments frequently failed to promote weight loss.  Researchers had reviewed randomised controlled trials data and concluded orlistat, sibutramine and rimonabant were of only ‘modest’ help in long-term weight loss.
 +
 +
:Average weight loss was less than 5%, below the thresholds for recommending a continuation of therapy by NICE. NICE advises anti-obesity drugs should be discontinued if patients have not lost at least 5% of their initial body weight after three months.
 +
 +
:Study leader Professor [[Gareth Williams]], professor of medicine at the [[University of Bristol]], said the studies showed the jury was still out on the long-term efficacy and safety of anti-obesity treatments. He added that they should not be given to patients who cannot lose weight through lifestyle changes alone.
 +
 +
:‘If patients can’t get on and take responsibility for their own lives, then flinging a pill at them is not going to do any useful work at all,’ he said.
 +
 +
:Professor Williams also warned of ‘insidious collateral damage’ if GSK was successful in its bid to make orlistat available over the counter in Europe.
 +
 +
:Dr [[David Haslam]], chair of the [[National Obesity Forum]], slammed the BMJ meta-analysis for being ‘full of errors’ and called it a ‘very bad’ paper. ‘Five percent weight loss is very clinically significant. What they are doing here is actually looking at average weight loss and some may not lose any weight but others may lose 10 or 20%.’Dr Haslam supported moves to make Orlistat available over the counter.<ref>[http://www.pulsetoday.co.uk/story.asp?sectioncode=23&storycode=4115938&c=2 . GPs divided on obesity drugs efficacy] Nigel Praities, 16 November 2007, PULSE,accessed 29 November 2007</ref>
  
 
==Affiliations==
 
==Affiliations==
Line 6: Line 22:
 
*[[National Obesity Forum]] - Chair
 
*[[National Obesity Forum]] - Chair
 
*[[Counterweight]] - board member
 
*[[Counterweight]] - board member
*[[Experts in Severe and Complex Obesity]]
+
*[[Experts in Severe and Complex Obesity]] - a group set up to improve access and treatment for severe and complex obesity on the NHS <ref>Jane Elliot, [http://www.bbc.co.uk/news/health-10953629 BBC News], 14 August 2010, accessed 25 October 2010. </ref>
 
*[[Robert Gordon University]], Aberdeen - Visiting Professor
 
*[[Robert Gordon University]], Aberdeen - Visiting Professor
 
*[[Chester University]] - Visiting Professor <ref> National Obesity Forum, [http://www.nationalobesityforum.org.uk/about-us/the-nof-trustees-mainmenu-159/122-dr-david-haslam.html Dr David Haslam], last accessed 6 October 2010. </ref>
 
*[[Chester University]] - Visiting Professor <ref> National Obesity Forum, [http://www.nationalobesityforum.org.uk/about-us/the-nof-trustees-mainmenu-159/122-dr-david-haslam.html Dr David Haslam], last accessed 6 October 2010. </ref>
 
*[[LighterLife]] UK Ltd - Chair of Medical Advisory Board <ref> LighterLife, [http://www.lighterlife.com/expert_advice.aspx Professor David Haslam], last accessed 6 October 2010. </ref>
 
*[[LighterLife]] UK Ltd - Chair of Medical Advisory Board <ref> LighterLife, [http://www.lighterlife.com/expert_advice.aspx Professor David Haslam], last accessed 6 October 2010. </ref>
*[[Foundations]] charity, Chair
+
*[[Foundations]] - Chair. Foundations is a charity that aims to provide the foundation of healthy diet and lifestyle in schools and in Primary Care, to prevent obesity and eating disorders.
 
*Bedfordshire and Hertfordshire Postgraduate Medical School - Staff <ref>Bedfordshire and Hertfordshire Postgraduate Medical School, [http://www.bhpms.ac.uk/staff/david-haslam Staff Profile Dr David W Haslam, MB BS DGM], accessed 5 October 2010. </ref>
 
*Bedfordshire and Hertfordshire Postgraduate Medical School - Staff <ref>Bedfordshire and Hertfordshire Postgraduate Medical School, [http://www.bhpms.ac.uk/staff/david-haslam Staff Profile Dr David W Haslam, MB BS DGM], accessed 5 October 2010. </ref>
 
*[[PCOS UK]] (the clinical wing of Verity, the charity for sufferers of Polycystic Ovarian Syndrome) - executive director and member of the Executive Council <ref> [http://www.pcos-uk.org.uk/people.asp PCOS UK Executive Council ], accessed 6 October 2010. </ref>
 
*[[PCOS UK]] (the clinical wing of Verity, the charity for sufferers of Polycystic Ovarian Syndrome) - executive director and member of the Executive Council <ref> [http://www.pcos-uk.org.uk/people.asp PCOS UK Executive Council ], accessed 6 October 2010. </ref>
*[[76 Harley Street]] - led its obesity services (dates needed)
+
*[[76 Harley Street]] - leads its obesity services (since at least 2008) <ref>76 Harley Street [http://www.76harleystreet.com/sections/team/david_haslam Our Specialists: David Haslam],accessed 24 October 2010 </ref>
*[[Primary Care Cardiovascular Journal]], and the [[British Journal of Cardiology]] - member of both editorial boards
+
*[[Primary Care Cardiovascular Journal]], and the [[British Journal of Cardiology]] - member of both editorial boards <ref>Bedfordshire and Hertfordshire Postgraduate Medical School, [http://www.bhpms.ac.uk/staff/david-haslam Staff Profile Dr David W Haslam, MB BS DGM], accessed 5 October 2010. </ref>
<ref>Bedfordshire and Hertfordshire Postgraduate Medical School, [http://www.bhpms.ac.uk/staff/david-haslam Staff Profile Dr David W Haslam, MB BS DGM], accessed 5 October 2010. </ref>
+
* [[iGlobalFitness]] - chairman, Medical Advisory Board, appointed 24 September 2010. iGlobalFitness describe themselves as 'the sustainable wellness experts'. <ref> [http://www.responsesource.com/releases/rel_display.php?relid=59486 iGlobalFitness appoint Prof David Haslam and Dr Matthew Capehorn to Medical Advisory Board ], press release 24 September 2010, via Responsesource, [[Nilmot PR]], accessed 6 October 2010. </ref>
* [[iGlobalFitness]] - chairman, Medical Advisory Board, appointed 24 September 2010. iGlobalFitness describe themselves as 'the sustainable wellness experts'. <ref> [http://www.responsesource.com/releases/rel_display.php?relid=59486 iGlobalFitness appoint Prof David Haslam and Dr Matthew Capehorn to Medical Advisory Board ], press release 24 September 2010, via Responsesource, [[Nilmot PR]], accessed 6 October 2010.
 
  
 
== Books ==
 
== Books ==
Line 28: Line 43:
 
<references/>
 
<references/>
  
[[Category:?]]
+
[[Category:Health|Haslam (GP and obesity specialist), David]][[Category:Healthcare Industry people|Haslam (GP and obesity specialist), David]]

Latest revision as of 16:04, 3 February 2011

Foodspin badge.png This article is part of the Foodspin project of Spinwatch.

Dr David W Haslam is a general practitioner with a special interest in obesity and and cardiometabolic disease. He is a physician in Obesity Medicine at the Centre for Obesity Research at Luton & Dunstable Hospital, and Chair of the UK's National Obesity Forum (NOF). [1]

Activities

Debate over obesity drugs efficacy

On 19 Nov 2007 a new study reported in the British Medical Journal (BMJ) showed that anti-obesity treatments frequently failed to promote weight loss. Researchers had reviewed randomised controlled trials data and concluded orlistat, sibutramine and rimonabant were of only ‘modest’ help in long-term weight loss.

Average weight loss was less than 5%, below the thresholds for recommending a continuation of therapy by NICE. NICE advises anti-obesity drugs should be discontinued if patients have not lost at least 5% of their initial body weight after three months.
Study leader Professor Gareth Williams, professor of medicine at the University of Bristol, said the studies showed the jury was still out on the long-term efficacy and safety of anti-obesity treatments. He added that they should not be given to patients who cannot lose weight through lifestyle changes alone.
‘If patients can’t get on and take responsibility for their own lives, then flinging a pill at them is not going to do any useful work at all,’ he said.
Professor Williams also warned of ‘insidious collateral damage’ if GSK was successful in its bid to make orlistat available over the counter in Europe.
Dr David Haslam, chair of the National Obesity Forum, slammed the BMJ meta-analysis for being ‘full of errors’ and called it a ‘very bad’ paper. ‘Five percent weight loss is very clinically significant. What they are doing here is actually looking at average weight loss and some may not lose any weight but others may lose 10 or 20%.’Dr Haslam supported moves to make Orlistat available over the counter.[2]

Affiliations

Books

  • Maguire, Terry., and Haslam, D. (date), The Obesity Epidemic and Its Management: A Textbook for Primary Healthcare Professionals on the Understanding, Management and Treatment of Obesity. London, England, Pharmaceutical Press.
  • Haslam, D., and Haslam, F., (2009) Fat, Gluttony and Sloth, Obesity in Art, Literature and Medicine. Liverpool, England, Liverpool University Press.

Resources

Notes

  1. National Obesity Forum, Dr David Haslam, last accessed 6 October 2010.
  2. . GPs divided on obesity drugs efficacy Nigel Praities, 16 November 2007, PULSE,accessed 29 November 2007
  3. Jane Elliot, BBC News, 14 August 2010, accessed 25 October 2010.
  4. National Obesity Forum, Dr David Haslam, last accessed 6 October 2010.
  5. LighterLife, Professor David Haslam, last accessed 6 October 2010.
  6. Bedfordshire and Hertfordshire Postgraduate Medical School, Staff Profile Dr David W Haslam, MB BS DGM, accessed 5 October 2010.
  7. PCOS UK Executive Council , accessed 6 October 2010.
  8. 76 Harley Street Our Specialists: David Haslam,accessed 24 October 2010
  9. Bedfordshire and Hertfordshire Postgraduate Medical School, Staff Profile Dr David W Haslam, MB BS DGM, accessed 5 October 2010.
  10. iGlobalFitness appoint Prof David Haslam and Dr Matthew Capehorn to Medical Advisory Board , press release 24 September 2010, via Responsesource, Nilmot PR, accessed 6 October 2010.